alexa Neuroblastoma Pathology: An Update
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

12th International Conference on Pediatric Pathology & Laboratory Medicine
March 15-16, 2017 London, UK

Hiroyuki Shimada
University of Southern California, USA
Children’s Hospital Los Angeles, USA
Keynote: J Clin Exp Pathol
DOI: 10.4172/2161-0681.C1.030
Abstract
Neuroblastoma is often used as an omnibus term for all types of peripheral neuroblastic tumors including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Tumors in this group are biologically diverse: Molecular/genomic properties of individual cases are closely related to their unique clinical behaviors. Biologically favorable tumors have a potential of spontaneous regression or tumor maturation and are often associated with a hyperdiploid pattern (whole chromosomal gains without structural abnormalities). Biologically favorable tumors have a potential of spontaneous regression or tumor maturation and are often associated with a hyperdiploid pattern (whole chromosomal gains without structural abnormalities). For neuroblastoma clinical trials, the children’s oncology group utilizes their risk-grouping system for patient stratification and protocol assignment based on the combination of clinical stage, age at diagnosis, International Neuroblastoma Pathology Classification, MYCN status, DNA index, and segmental chromosomal aberrations. Estimated survival rate for the non-highrisk patients is ~90% with surgery alone (low risk) or with biopsy/surgery and moderate chemotherapy (intermediate risk). In contrast, estimated survival rate for the high-risk patients remains as low as 45~50% even after intensive treatment followed by stem-cell transplantation. Continuous efforts are being made for discovery of actionable/druggable targets in high-risk neuroblastomas. Those potential targets include: ALK activating mutation/amplification (dysregulating cell signaling and leading to uncontrolled proliferation of neuroblasts); TERT rearrangement and ATRX/DAXX mutation (preventing neuroblasts from telomere-mediated senescence); and MYC family protein overexpression- a new concept of highly aggressive "MYC family-driven neuroblastomas" with augmented expression of MYCN or MYC protein, also morphologically characterized by nucleolar hypertrophy (promoting MYC/MAX heterodimer formation for activating down-stream gene targets).
Biography

Hiroyuki Shimada has completed his MD and PhD from the Yokohama City University, School of Medicine and Ohio State University College of Medicine, respectively. He is a Professor of Pathology at the University of Southern California Keck School of Medicine, Founder of International Neuroblastoma Pathology Classification and Director of COG Neuroblastoma Pathology Reference Laboratory. He has been reviewing ~700 neuroblastoma cases per year from US, Canada, Australia and New Zealand and participating in various clinical and translational research activities in the field of Pediatric Oncology. He has authored/co-authored more than 180 papers.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords